本帖最后由 老马 于 2012-1-13 21:20 编辑
+ b+ n( j+ ?, L/ y X0 N. ^ }7 T& d1 o9 t
爱必妥和阿瓦斯丁的比较6 |$ z9 m* O. F* c, ~: ]! [6 _% m
) V8 ` }/ E5 n: C1 m4 g# l
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/. ^, [7 x* S1 i$ q6 f+ S
& T6 M7 E( Q7 A+ l2 w8 U8 y7 f/ }
, v7 Q6 P% O4 \3 { d* ^" }
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
, l. H0 r5 Q4 p==================================================' |+ K2 c3 i$ ]" D5 X# R
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
/ K$ A* U) P6 D7 FPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.6 |0 O$ \, \1 p
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.) B$ Q& H( u4 l' Y; n
|